Oncternal Therapeutics
- Company typePrivate
- Founded2013
- HeadquartersEncinitas, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Oncternal Therapeutics firmographics
Firmographics- Name
- Oncternal Therapeutics
- Legal name
- Oncternal Therapeutics
- Website
- https://oncternal.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Oncternal Therapeutics industry classification
Industry- Product category
- Clinical-Stage Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Oncternal Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Encinitas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Oncternal Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Oncternal Therapeutics product offering
Product offeringCore offering
Oncternal Therapeutics was a clinical-stage oncology company developing a diverse pipeline of treatments for cancers, with a focus on cell therapy approaches. The company is no longer operating as of 2025 and had not yet commercialized any approved product.
Product overview
Oncternal Therapeutics was a clinical-stage oncology company based in San Diego, CA that is no longer operating as of 2025. The company was focused on developing cancer therapeutics but specific product names and details are not available from the provided source material. The company shutdown is noted in the 2025 Biotech Graveyard report alongside other cell therapy-focused biotechs that ceased operations.
Differentiator
Problem solved
Functional benefit
Companies that use Oncternal Therapeutics
Customer profileIdeal customer profiles1 record
Oncternal Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oncternal Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Oncternal Therapeutics competitors and assessment
Company assessmentDirect peers
- Marker Therapeutics: Clinical-stage cell therapy company developing multi-tumor-associated antigen (TAA)-specific T-cell therapies for oncology. Comparable as a small clinical-stage oncology biotech focused on T-cell based modalities facing similar capital and regulatory headwinds.
- Precision BioSciences: Clinical-stage gene editing company developing allogeneic CAR T-cell therapies for oncology. Directly comparable as a clinical-stage oncology cell therapy biotech facing similar capital and clinical execution risks.
- Adaptimmune Therapeutics: Clinical-stage cell therapy oncology company developing TCR-based therapies for solid tumors. Highly comparable as a small-cap clinical-stage oncology biotech with similar capital intensity and regulatory exposure; part of the broader 2025 biotech closure cohort.
- Iovance Biotherapeutics: Clinical-stage and recently commercial cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable as a cell therapy-focused oncology peer with similar clinical pipeline dynamics and capital needs.
- Fate Therapeutics: Clinical-stage cell therapy oncology company developing off-the-shelf iPSC-derived NK and T-cell therapies. Directly comparable as a clinical-stage oncology peer focused on next-generation cell therapy modalities with similar capital requirements.
- Allogene Therapeutics: Clinical-stage allogeneic CAR T-cell therapy company for hematologic malignancies and solid tumors. Closely comparable in therapeutic modality (cell therapy for oncology), stage of development, and capital structure profile.
- Aeglea BioTherapeutics: Clinical-stage biotech focused on rare disease and oncology enzyme therapies that closed in 2025. Directly comparable as a small clinical-stage biotech that ceased operations due to similar financial and regulatory pressures.
- Harpoon Therapeutics: Clinical-stage immunotherapy company developing T-cell engagers for oncology; was acquired by Merck in 2024. Comparable as a small clinical-stage oncology biotech that ultimately exited via acquisition rather than commercialization.
- Infinity Pharmaceuticals: Clinical-stage oncology company developing small molecule therapies for hematologic malignancies and solid tumors. Comparable as a small clinical-stage oncology biotech with similar capital structure and pipeline risk profile.
Emerging players
- Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies including oncology applications. Comparable as a clinical-stage biotech with high capital intensity, though focused on gene editing rather than traditional oncology modalities.
Market position
Strengths1 record
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Oncternal Therapeutics social profiles
Digital presenceOncternal Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncternal Therapeutics leadership team
Management profileNumber of profiles
Oncternal Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncternal Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncternal Therapeutics
What does Oncternal Therapeutics do?
Oncternal Therapeutics was a clinical-stage oncology company developing a diverse pipeline of treatments for cancers, with a focus on cell therapy approaches. The company is no longer operating as of 2025 and had not yet commercialized any approved product.
Is Oncternal Therapeutics a public or private company?
Oncternal Therapeutics is a private company. It is classified as public and is currently closed.
When was Oncternal Therapeutics founded?
Oncternal Therapeutics was founded in 2013. It employs 11 to 50 people.
Where is Oncternal Therapeutics based?
Oncternal Therapeutics is headquartered in Encinitas, United States, in the North America region.
Who are Oncternal Therapeutics's main competitors?
Direct peers on record are Marker Therapeutics, Precision BioSciences, Adaptimmune Therapeutics, Iovance Biotherapeutics, Fate Therapeutics, Allogene Therapeutics, Aeglea BioTherapeutics, Harpoon Therapeutics and Infinity Pharmaceuticals. Editas Medicine is listed as an emerging player.
Does Oncternal Therapeutics have an API?
No public API is recorded for Oncternal Therapeutics.
What industry is Oncternal Therapeutics in?
Oncternal Therapeutics's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.